Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04686305
Title Phase Ib Study of the Safety of T-DXd and Durvalumab With Chemotherapy in Advanced or Metastatic HER2+ Non-squamous NSCLC (DL03)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AstraZeneca

lung non-squamous non-small cell carcinoma


Durvalumab + Pemetrexed Disodium + Trastuzumab deruxtecan

Carboplatin + Durvalumab + Trastuzumab deruxtecan

Durvalumab + Trastuzumab deruxtecan

Cisplatin + Durvalumab + Trastuzumab deruxtecan

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL

Additional content available in CKB BOOST